Guardant Health (NASDAQ:GH – Get Rating) will release its earnings data after the market closes on Thursday, August 4th. Analysts expect Guardant Health to post earnings of ($1.25) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Guardant Health (NASDAQ:GH – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.02. Guardant Health had a negative net margin of 107.20% and a negative return on equity of 62.68%. The firm had revenue of $96.10 million during the quarter, compared to the consensus estimate of $95.71 million. During the same period last year, the firm posted ($1.06) EPS. The firm’s quarterly revenue was up 22.2% on a year-over-year basis. On average, analysts expect Guardant Health to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Guardant Health Trading Up 4.2 %
Shares of GH stock opened at $50.24 on Thursday. Guardant Health has a 12-month low of $27.65 and a 12-month high of $133.82. The company has a market capitalization of $5.12 billion, a P/E ratio of -12.19 and a beta of 0.71. The firm has a 50-day moving average price of $42.68 and a 200 day moving average price of $56.32. The company has a quick ratio of 4.71, a current ratio of 4.87 and a debt-to-equity ratio of 2.13.
Hedge Funds Weigh In On Guardant Health
Ad Oxford Club
Is Gold is Trouble?
The rules of money are quickly being rewritten. Gold is losing its luster. But it could get worse… much worse. I’ve outlined what’s happening… and what you can do right now to get prepared.
Click here to get the details.
Large investors have recently modified their holdings of the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in shares of Guardant Health in the first quarter valued at about $89,000. Avalon Investment & Advisory grew its stake in shares of Guardant Health by 13.7% in the first quarter. Avalon Investment & Advisory now owns 5,081 shares of the company’s stock valued at $337,000 after acquiring an additional 612 shares in the last quarter. MetLife Investment Management LLC acquired a new position in shares of Guardant Health in the first quarter valued at about $385,000. US Bancorp DE grew its stake in shares of Guardant Health by 5.2% in the first quarter. US Bancorp DE now owns 12,808 shares of the company’s stock valued at $849,000 after acquiring an additional 632 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new position in shares of Guardant Health in the first quarter valued at about $949,000. 93.69% of the stock is owned by institutional investors.
Analyst Ratings Changes
GH has been the subject of several analyst reports. Citigroup lowered their price target on shares of Guardant Health from $120.00 to $100.00 in a research report on Friday, May 6th. Piper Sandler initiated coverage on shares of Guardant Health in a research report on Thursday, June 2nd. They set an “overweight” rating and a $65.00 price target for the company. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health has an average rating of “Buy” and a consensus target price of $131.73.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Guardant Health right now?
Before you consider Guardant Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Guardant Health wasn’t on the list.
While Guardant Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
